Intero Biosystems Advances Lab-Grown Gut Models as Alternative to Animal Drug Testing

The Problem With Current Drug Testing

Pharmaceutical development has historically depended on animal models to evaluate drug safety and efficacy, but the approach carries a fundamental limitation: what works in mice or other test animals frequently fails to translate to human biology. The result is a costly and time-consuming pipeline where most drug candidates ultimately fail during clinical trials. Researchers across the biotech and pharma sectors increasingly recognize this disconnect and are seeking alternative testing methods that more accurately reflect human physiology.

Intero's Organoid Solution

Intero Biosystems, a Denver-based company spun out of the University of Michigan, is developing human intestinal organoids—lab-grown tissue structures that replicate the complexity of the actual gut. The company's flagship product, GastroScreen, consists of organoids approximately one millimeter across that contain multiple cell and tissue types found in real human intestines, distinguishing them from simpler cellular models that replicate only isolated gut components. The startup manufactures these living miniature organs using induced pluripotent stem cells derived from blood samples, allowing for potential customization to individual patients while enabling scalable production.

Intero ships roughly 100 organoids at a time in tubes to pharmaceutical, biotech, food, and chemical companies. Customers can use them as healthy tissue models or deliberately induce disease-like conditions to observe how different compounds affect the tissue. The company also provides supplementary services including nutrient mixes, experimental chemicals, and custom study designs that combine laboratory testing with data analysis. Beyond drug safety screening, the organoids enable disease research and testing for gastrointestinal toxicity.

Regulatory Tailwinds and Market Opportunity

The business case has strengthened considerably due to recent regulatory shifts. In April 2025, the FDA announced plans to reduce reliance on animal testing in drug development and promoted organoids, organs-on-chip devices, and computational models as viable alternatives. Subsequently, the FDA issued draft guidance in March 2026 detailing how drug developers should validate non-animal testing methods when supporting regulatory submissions. While the guidance establishes a framework without endorsing specific technologies, it has catalyzed interest among pharmaceutical companies previously hesitant about alternatives to animal models. U.S. legal changes permitting non-animal testing methods in certain contexts have further encouraged pharma companies to explore organoid technology for internal use.

Intero, founded in 2024, currently operates with seven employees and serves nearly ten customers. The company generated over $400,000 in revenue from the fourth quarter of 2025 through the third quarter of 2026. It previously raised $2.3 million in a pre-seed funding round.

Validation Stage and Competitive Positioning

While enthusiasm is building, Intero remains in the middle of a three-stage validation process demonstrating that GastroScreen accurately predicts human drug responses. The company has completed the first stage by confirming that its organoids contain key human gut tissues. In the current second stage, Intero is testing well-known drugs with documented human effects; results show that GastroScreen responds appropriately to inflammation-reducing medications and compounds known to damage intestinal tissue. The final validation stage, now underway with multiple pharmaceutical partners, will directly compare GastroScreen predictions against pharmaceutical companies' existing animal and clinical data for both established compounds and new candidates.

Intero competes in a growing market alongside established players including Altis Biosystems (stem cell-derived intestinal models), InSphero (patient-derived organoids for toxicity testing), and MIMETAS (organ-on-chip microfluidic systems). Intero differentiates itself through claimed advantages in model complexity and production scalability. The induced pluripotent stem cell approach enables both patient-specific customization and easier manufacturing scale-up compared to organoids derived from patient tissue samples collected during procedures such as colonoscopies.

Growth Trajectory and Future Ambitions

In the near term, Intero is focused on manufacturing scale-up. The company currently produces a few thousand organoids per batch and is automating production processes with a target of generating hundreds of thousands per batch. Beyond immediate production goals, the startup envisions a transition into personalized medicine, where patient-derived organoids could predict individual drug responses before treatment begins. The company's most ambitious long-term vision is developing an artificial intestine that would leverage the manufacturing capabilities and patient-specific biological data generated through its organoid platform.

Interestingly, Intero does not use AI to construct its organoids. Instead, leadership sees organoids as a means to generate biological datasets that AI models require, with plans to license such data to pharmaceutical and AI companies. This approach positions the company as a data provider within the broader AI-driven drug discovery ecosystem rather than an AI developer itself.